AI assistant
INOVIO PHARMACEUTICALS, INC. — Director's Dealing 2021
Mar 12, 2021
34008_dirs_2021-03-12_d44aee15-7050-4233-ad69-b545b1530f81.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INOVIO PHARMACEUTICALS, INC. (INO)
CIK: 0001055726
Period of Report: 2021-03-11
Reporting Person: Shea Jacqueline Elizabeth (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-11 | Common Stock | M | 59737 | — | Acquired | 98272 | Direct |
| 2021-03-11 | Common Stock | F | 25974 | $10.57 | Disposed | 72298 | Direct |
| 2021-03-12 | Common Stock | S | 16881 | $10.06 | Disposed | 55417 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-11 | Restricted Stock Unit | $ | M | 59737 | Disposed | Common Stock (59737.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.
F4: These transactions were executed in multiple trades at prices ranging from $9.96 to $10.18, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.